Relay Therapeutics is a clinical-stage precision medicine company that designs small-molecule drugs by modeling how proteins move, not only their static structures. Its Dynamo platform combines computational protein dynamics with experimental validation to pursue hard-to-drug targets, primarily in oncology. The pipeline has focused on genetically defined cancers and related signaling pathways. The company serves the specialty oncology development space rather than commercial primary care.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0.7 | — | -70.4 | — |
| Q3 2025 | 0 | — | -74.2 | — |
| Q4 2025 | 7 | — | -54.9 | — |
| Q1 2026 | 3 | — | -73.3 | — |
| Q2 2026 | 0.3 | -48.3% | -83.7 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Aya Gold & Silver Inc. (AYA), WSFS Financial Corporation (WSFS), Adaptive Biotechnologies Corporation (ADPT), AXT, Inc. (AXTI), iRhythm Holdings, Inc. (IRTC), CVB Financial Corp. (CVBF)